Inflammatory status and prognosis of locally advanced non-small cell lung cancer

This publication has 25 references indexed in Scilit:

• Immunological Status May Predict Response to Nivolumab in Non-small Cell Lung Cancer without Driver Mutations
  Anticancer Research, 2017
• Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy
  The Oncologist, 2017
• Association of intra‐tumoral tumour‐infiltrating lymphocytes and neutrophil‐to‐lymphocyte ratio is an independent prognostic factor in non‐small cell lung cancer
  The Clinical Respiratory Journal, 2015
• Mechanism of Action of IL-7 and Its Potential Applications and Limitations in Cancer Immunotherapy
  International Journal of Molecular Sciences, 2015
• Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study
  Cancer Medicine, 2015
• Neutrophil extracellular traps in cancer progression
  Cellular and Molecular Life Sciences, 2014
• Immunity, Inflammation, and Cancer
  Cell, 2010
• IKK/NF‐κB and STAT3 pathways: central signalling hubs in inflammation‐mediated tumour promotion and metastasis
  EMBO Reports, 2009
• Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas
  Cancer Research, 2009
• Persistent Lymphocytopenia as a Diagnostic Feature of Bronchogenic Carcinoma
  Chest, 1980